Validating a Multi-Contract Genome Editing Feasibility Framework

Published: March 2024
Authors: Helix Research Team
Topic: Empirical validation of the Constraint → Strategy Engine across Prime Editor, Base Editor, and Cas12a modalities

---

Abstract

We present empirical validation of a deterministic feasibility framework that generalizes across genome editing systems. The framework uses explicit, versioned "detection contracts" with system-specific constraints (PBS/RT length for Prime Editors, bystander burden for Base Editors, GC content for Cas12a) and produces a comparable "Correctability Score" (CS) across modalities.

Validation against 30 curated literature cases shows:

• Spearman ρ = 0.811 between CS and published experimental outcomes
• F1 = 0.872 for binary tractability classification
• Strong correlation within all three modalities (ρ = 0.73-0.99)
• Appropriate conservatism (model underpredicts rather than overpromises)

The framework is validated as a comparative tractability metric for therapeutic target prioritization, not as an exact efficiency predictor.

---

1. Introduction

The Problem

Genome editing therapeutic development requires answering: "Can this variant be edited, and with what approach?"

Current tools fall into two categories:

1. Guide design tools (CHOPCHOP, PrimeDesign) — optimize specific guides
2. Feasibility scores — aggregate factors into scalars

Neither answers the prioritization question well. Single-score approaches obscure whether low scores mean "hard but solvable" or "not worth pursuing."

Our Approach

The Constraint → Strategy Engine separates three concepts:

• Feasibility: How technically difficult?
• Strategy: What solutions exist?
• Correctability: Composite actionability (CS = √FS × SS)

Key innovation: Multi-contract architecture with explicit, versioned constraints:

• Prime Editor: PBS quality, RT complexity, bystander risk
• Base Editor: Window position, bystander burden, purity
• Cas12a: PAM quality, GC penalty, targeting density

Validation Question

Does CS correlate with published experimental outcomes? If so, CS can serve as a comparative prioritization metric across editing systems.

---

2. Methods

2.1 Benchmark Corpus

Distribution (anti-cherry-picking):

• Strong successes: 7
• Borderline/middling: 10
• Poor/failed: 6
• Pain point stress cases: 7

Sources:

• Foundational papers (2016-2019): 14 cases
• Recent papers (2020+): 16 cases
• Max from single source: 3 cases

2.2 Contracts

All contracts use non-linear composition: CS = component_product × √coverage

2.3 Evaluation Views

View 1: Rank Correlation — Spearman ρ between CS and published efficiency

View 2: Calibration — Mean observed efficiency by CS tier

View 3: Binary Classification — F1 score for tractable vs not tractable (threshold: CS ≥ 0.15)

View 4: Outlier Audit — Top 5 discrepancies, categorized

2.4 Success Criteria (Pre-declared)

---

3. Results

3.1 Rank Correlation

Interpretation: CS preserves rank ordering across all modalities. Strongest in Cas12a (well-defined constraints), moderate in Base Editor (bystander complexity adds variance).

3.2 Calibration

Trend: Clear monotonic increase from Tier E to Tier A. Minor local inversion between D and C.

3.3 Binary Classification

Confusion Matrix:

• True Positives: 17
• False Positives: 4
• True Negatives: 8
• False Negatives: 1

Metrics:

Interpretation: High precision and recall for tractability classification.

3.4 Outlier Analysis

Top 5 outliers (all underpredictions):

Pattern: Model is conservative. All major outliers are cases where the model predicted lower efficiency than observed.

Why: Original/base systems often outperform contract assumptions; HEK293T permissivity; engineered variants (pegRNA, ABE8e) exceed base models.

Implication: Framework rarely overpromises — acceptable for prioritization.

---

4. Discussion

4.1 What Works

1. Cross-system comparability: CS correlates across Prime, Base, and Cas12a
2. Rank preservation: CS orders designs correctly (ρ = 0.81)
3. Tractability classification: F1 = 0.87 for go/no-go decisions
4. Appropriate conservatism: Underpredicts more than overpredicts

4.2 Limitations

Explicitly not modeled:

• Chromatin context (accessibility, nucleosomes)
• DNA repair pathway activity
• Delivery efficiency variation
• Cell type-specific effects
• Assay method differences

Impact: Framework may underestimate optimized or highly permissive systems.

4.3 Claim Boundary

"CS is a comparative in-silico tractability score. It is designed to rank candidate edits under modeled constraints, not to estimate exact experimental efficiency."

Appropriate use:

• Portfolio prioritization
• Modality selection
• Resource allocation
• Risk flagging

Inappropriate use:

• Predicting exact efficiency percentages
• Replacing experimental validation

---

5. Conclusions

The multi-contract feasibility framework demonstrates strong empirical alignment with published genome editing outcomes:

• Rank correlation: ρ = 0.81 overall
• Classification: F1 = 0.87
• Cross-modality: Validated across Prime, Base, and Cas12a
• Conservatism: Appropriate for prioritization

CS is validated as a comparative tractability metric for therapeutic development decisions.

---

6. Data and Code

Validation artifacts:

• Validation Contract (frozen protocol)
• Curated Corpus (30 cases)
• [Frozen Outputs (locked)]/decision_support/cse_data_download)
• Evaluation Results

Frozen output hash: 99648bda51771202

---

References

1. Anzalone et al. (2019). Search-and-replace genome editing. Nature.
2. Komor et al. (2016). Programmable editing of a target base. Nature.
3. Nishida et al. (2016). Targeted nucleotide editing. Science.
4. Kleinstiver et al. (2016). Genome-wide profiling of Cas12a. Nature Biotechnology.
5. Nelson et al. (2022). Engineered pegRNAs. Nature Biotechnology.

---

Citation:

@article{helix_cse_validation_2024,
  title={Validating a Multi-Contract Genome Editing Feasibility Framework},
  author={Helix Research Team},
  year={2024},
  url={https://helix.dev/articles/validation_cse_v3.2}
}

---

Tags: #genome-editing #feasibility #validation #prime-editing #base-editing #cas12a #computational-biology